Hs-cTnT as a risk factor for the primary end point ( cardiovascular death , nonfatal myocardial infarction , and nonfatal stroke ; n = @ ) , as well as all-cause mortality ( n = @ ) , cardiovascular mortality ( n = @ ) , and the composite of cardiovascular mortality and hospitalization from worsening of HF ( n = @ ) , was investigated in @ patients ( @ years ; New York Heart Association -LSB- NYHA -RSB- class II-IV , ischemic systolic HF ) randomly assigned to @ mg rosuvastatin or placebo .